Xpose Therapeutics Inc is early-stage drug discovery company leveraging a cutting-edge approach using experimental information on 3D protein-ligand interactions as a starting point to discover and develop target-specific small molecule cancer therapeutics for traditionally âundruggableâ targets.. Founder boot-strapped the firm to a self-sustaining, revenue generating and profitable entity in second year by working with multiple pharma and biotech companies and academic drug discovery. Firm organized around business and technology development and deployment for high-throughput protein x-ray crystallography-driven drug discovery and development of fragment- and structure-based drug discovery programs. Focus is on DNA damage response (DDR) proteins and their demonstrated roles in cancer. The compounds discovered and developed can be deployed in a multi-pronged approach across multiple modalities: monotherapy involving conventional enzyme inhibition; synthetic lethality (SL); targeted-protein degradation; and combinatorial therapy with other genotoxins and cytostatics, thereby providing a significantly large therapeutic landscape to help a wide variety of patient
